• Zarnab Zainab PEMH rwp
  • Naveed Akhtar Malik PEMH rwp
  • Shanza Obaid PEMH rwp
  • Saqib Malik AMC
  • Kanza Aftab PEMH rwp
  • Maimoona Mumtaz PEMH rwp
  • Alia Pervaiz Comsat Islamabad
  • Zainab Syed AMC


Background: Acne vulgaris has been a common clinical condition. Due to. high prevalence and unclear etio-pathogenesis of acne vulgaris, large number of treatment options have been available across the globe. Limited work has been done to explore the options which may manage or prevent these adverse effects and improve the adherence to the prescribed medications. We therefore conducted this trial to look for effectiveness of oral omega 3 in reducing mucocutaneous side effects of oral isotretinoin in patients with acne vulgaris. Objective: To look for effectiveness of oral omega 3 in reducing mucocutaneous side effects of oral isotretinoin in patients with acne vulgaris. It was a randomized control trial conducted at Department of Dermatology Pak Emirates Military Hospital Rawalpindi. Ten months, June 2019 to May 2020. Methods. A total of 60 patients of acne vulgaris put on oral isotretinoin by consultant dermatologist were included in the study. Patients were randomized into groups by lottery method. Group A received the placebo along with oral isotretinoin while Group B received oral omega 3 in standard dose in addition to oral isotretinoin. Comparison was made in both the groups regarding common mucocutaneous side effects. Results Out of 60patients with acne vulgaris and put on isotretinoin included in the study, 26 (43.3%) received placebo in addition to isotretinoin while 34 (56.7%) received omega 3 in addition to isotretinoin. Forty (66.7%) patients were female while 20 (33.3%) were male. Cheilitis 35 (58.3%) was the commonest side effect followed by lip dryness 33 (55%). Application of chi-square test revealed that cheilitis, lip dryness and xerosis were significantly found in more patients who received placebo as compared to those who received omega 3 along with isotretinoin. Conclusion Mucocutaneous side effects were a very common finding among patients of acne vulgaris managed with isotretinoin. Cheilitis was the most reported mucocutaneous side effects among the target population. This RCT demonstrated that omega 3 was superior to placebo in order to prevent or manage cheilitis, xerosis or dry lips. Keywords: Acne vulgaris; Isotretinoin; Mucocutaneous; Omega 3

Author Biographies

Zarnab Zainab, PEMH rwp

Dermatology/ Trainee

Naveed Akhtar Malik, PEMH rwp

Dermatology/ Professor

Shanza Obaid, PEMH rwp

Dermatology/ Trainee

Saqib Malik, AMC

Medicine/ Associate Professor

Kanza Aftab, PEMH rwp

Dermatology/ Trainee

Maimoona Mumtaz, PEMH rwp

Dermatology/ Trainee

Alia Pervaiz, Comsat Islamabad

Research Associate

Zainab Syed, AMC

Medicine/ Trainee



Seth D, Cheldize K, Brown D, Freeman EF. Global Burden of Skin Disease: Inequities and Innovations. Curr Dermatol Rep. 2017;6(3):204–210. doi:10.1007/s13671-017-0192-7

Kaushik M, Gupta S, Mahendra A. Living with Acne: Belief and Perception in a Sample of Indian Youths. Indian J Dermatol. 2017;62(5):491–497. doi:10.4103/ijd.IJD_100_16

Cong TX, Hao D, Wen X, Li XH, He G, Jiang X. From pathogenesis of acne vulgaris to anti-acne agents. Arch Dermatol Res. 2019;311(5):337-349. doi: 10.1007/s00403-019-01908-x

Oon HH, Wong SN, Aw DCW, Cheong WK, Goh CL, Tan HH. Acne Management Guidelines by the Dermatological Society of Singapore. J Clin Aesthet Dermatol. 2019;12(7):34–50.

Seago M, Shumaker PR, Spring LK, Alam M, Al-Niaimi F, Rox Anderson R et al. Laser Treatment of Traumatic Scars and Contractures: 2020 International Consensus Recommendations. Lasers Surg Med. 2020;52(2):96-116. doi: 10.1002/lsm.23201.

Kravvas G, Al-Niaimi F. A systematic review of treatments for acne scarring. Part 2: Energy-based techniques. Scars Burn Heal. 2018;4:2059513118793420. Published 2018 Aug 16. doi:10.1177/2059513118793420

Rademaker M. Adverse effects of isotretinoin: A retrospective review of 1743 patients started on isotretinoin. Australas J Dermatol. 2010;51(4):248‐253. doi:10.1111/j.1440-0960.2010.00657.x.

Layton A. The use of isotretinoin in acne. Dermatoendocrinol. 2009;1(3):162‐169. doi:10.4161/derm.1.3.9364

Mirnezami M, Rahimi H. Is Oral Omega-3 Effective in Reducing Mucocutaneous Side Effects of Isotretinoin in Patients with Acne Vulgaris?. Dermatol Res Pract. 2018;2018:6974045. Published 2018 May 29. doi:10.1155/2018/6974045

Ahmed I, Wahid Z, Nasreen S. Adverse effects of systemic isotretinointherapy: a study of 78 patients. J Pak Assoc Dermatol. 2005;15(1):242-246.

Brzezinski P, Borowska K, Chiriac A, Smigielski J. Adverse effects of isotretinoin: A large, retrospective review. Dermatol Ther. 2017;30(4):10.1111/dth.12483. doi:10.1111/dth.12483

Sutaria AH, Masood S, Schlessinger J. Acne Vulgaris. [Updated 2019 Dec 13]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK459173/

Abdelmaksoud A, Lotti T, Anadolu R, et al. Low dose of isotretinoin: A comprehensive review. Dermatol Ther. 2020;33(2):e13251. doi:10.1111/dth.13251

Ton J, Korownyk C. Omega-3 supplements for dry eye. Can Fam Physician. 2018;64(11):826.

Babar O, Mobeen A. Prevalence and Psychological Impact of Acne Vulgaris in Female Undergraduate Medical Students of Rawalpindi and Islamabad, Pakistan. Cureus. 2019;11(9):e5722. Published 2019 Sep 22. doi:10.7759/cureus.5722

Cannizzaro MV, Dattola A, Garofalo V, Del Duca E, Bianchi L. Reducing the oral isotretinoin skin side effects: efficacy of 8% omega-ceramides, hydrophilic sugars, 5% niacinamide cream compound in acne patients. G Ital Dermatol Venereol. 2018;153(2):161‐164. doi:10.23736/S0392-0488.17.05742-X.

Fabbrocini G, Cameli N, Lorenzi S, et al. A dietary supplement to reduce side effects of oral isotretinoin therapy in acne patients. G Ital Dermatol Venereol. 2014;149(4):441‐445.

Kus S, Gün D, Demirçay Z, Sur H. Vitamin E does not reduce the side-effects of isotretinoin in the treatment of acne vulgaris. Int J Dermatol. 2005;44(3):248‐251. doi:10.1111/j.1365-4632.2004.02072.x



Most read articles by the same author(s)

<< < 1 2